Core Scientific (CORZ) Cash & Equivalents (2021 - 2026)

Core Scientific has disclosed Cash & Equivalents across 6 years of filings, most recently posting $1.8 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 204.42% year-over-year to $1.8 billion; the TTM figure through Jun 2026 stood at $1.8 billion (up 204.42% YoY), while the FY2025 annual figure was $311.4 million, down 62.76% from the prior year.
• Cash & Equivalents came in at $1.8 billion for Q2 2026 at Core Scientific, up from $1.0 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.8 billion in Q2 2026 to a low of $15.9 million in Q4 2022.
• Average Cash & Equivalents over 5 years is $365.0 million, with a median of $113.3 million recorded in 2022.
• The largest YoY upside for Cash & Equivalents was 6186.29% in 2022 against a maximum downside of 86.52% in 2022.
• Over 5 years, Cash & Equivalents stood at $15.9 million in 2022, then jumped by 217.36% to $50.4 million in 2023, then surged by 1558.82% to $836.2 million in 2024, then slumped by 62.76% to $311.4 million in 2025, then surged by 468.36% to $1.8 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.8 billion in Q2 2026, $1.0 billion in Q1 2026, and $311.4 million in Q4 2025.